Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-42 and Pazopanib in advanced soft tissue sarcoma and renal cell carcinoma
NCT02795819Phase 1Terminated
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AR-42 in renal cell carcinoma (RCC) and soft tissue sarcoma (STS), sponsored by Virginia Commonwealth University. Started Jul 2016; status: terminated.
02
Drugs
AR-42
03
Conditions
renal cell carcinoma (RCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02795819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795819.